The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
MGMT Status as a Clinical Biomarker in Glioblastoma
Open accessAbstract
Glioblastoma is the most common primary malignant brain tumor. Although current standard therapy extends median survival to ~15 months, most patients do not have sustained response to treatment. While O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is accepted as a prognostic and promising predictive biomarker in glioblastoma, its value in informing treatment decisions for glioblastoma patients is still debatable. Discrepancies between MGMT promoter methylation status and treatment response in some patients may stem from inconsistencies between MGMT methylation and expression levels in glioblastoma. Here, we discuss MGMT as a biomarker and elucidate the discordance between MGMT methylation, expression, and patient outcome, which currently challenges the implementation of this biomarker in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy131 · Cited by 2,138
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
MGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 579
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 390
Bady, P., Sciuscio, D., Diserens, A.-C., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 344
Mansouri, A., Hachem, L. D., Mansouri, S., Nassiri, F., Laperriere, N. J., Xia, D., Lindeman, N. I., Wen, P. Y., Chakravarti, A., Mehta, M. P., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noy132 · Cited by 340
Self-citationDunn, J., Baborie, A., Alam, F., Joyce, K., Moxham, M., Sibson, R., Crooks, D., Husband, D., Shenoy, A., Brodbelt, A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605127 · Cited by 321
Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M. C., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 297
Preusser, M., Charles Janzer, R., Felsberg, J., Reifenberger, G., Hamou, M., Diserens, A., Stupp, R., Gorlia, T., Marosi, C., Heinzl, H., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00153.x · Cited by 242
Christmann, M., Verbeek, B., Roos, W. P., & Kaina, B. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.06.002 · Cited by 241
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M. C., Koeppen, S., Ketter, R., Weiler, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95680 · Cited by 234
Molenaar, R. J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J. W. M., Boots-Sprenger, S. H. E., Wesseling, P., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou005 · Cited by 207
Temozolomide in malignant gliomas: current use and future targets
Villano, J. L., Seery, T. E., & Bressler, L. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1050-5 · Cited by 202
Karayan-Tapon, L., Quillien, V., Guilhot, J., Wager, M., Fromont, G., Saikali, S., Etcheverry, A., Hamlat, A., Loussouarn, D., Campion, L., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0031-1 · Cited by 188
DNA repair mechanisms and their clinical impact in glioblastoma
Erasimus, H., Gobin, M., Niclou, S., & Van Dyck, E. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.05.005 · Cited by 188
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Everhard, S., Tost, J., El Abdalaoui, H., Crinière, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle-Donadey, F., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-001 · Cited by 177
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 166
Hegi, M. E., Genbrugge, E., Gorlia, T., Stupp, R., Gilbert, M. R., Chinot, O. L., Nabors, B., Jones, G., Criekinge, W. V., Straub, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3181 · Cited by 162
Rajapakse, V. N., Luna, A., Yamade, M., Loman, L., Varma, S., Sunshine, M., Iorio, F., Sousa, F. G., Elloumi, F., Aladjem, M. I., et al. (2018) · iScience · doi:10.1016/j.isci.2018.11.029 · Cited by 161
Self-citationMalley, D. S., Hamoudi, R., Kocialkowski, S., Pearson, D. M., Collins, V. P., & Ichimura, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0803-5 · Cited by 152
Cabrini, G., Fabbri, E., Nigro, C. L., Dechecchi, M. C., & Gambari, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3026 · Cited by 146
Temozolomide in the Era of Precision Medicine
Thomas, A., Tanaka, M., Trepel, J. B., Reinhold, W. C., Rajapakse, V. N., & Pommier, Y. G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2983 · Cited by 145
Self-citationUno, M., Oba‐Shinjo, S. M., Camargo, A. A., de Moura, R. P., de Aguiar, P. H. P., Cabrera, H. N., Begnami, M. F. S., Rosemberg, S., Teixeira, M. J., & Marie, S. K. N. (2011) · Clinics · doi:10.1590/s1807-59322011001000013 · Cited by 134
McFaline‐Figueroa, J. L., Braun, C. J., Stanciu, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3616 · Cited by 131
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme
Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1151 · Cited by 131
O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems
Silber, J. R., Bobola, M. S., Blank, A., & Chamberlain, M. C. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.004 · Cited by 125
Kreth, S., Thon, N., Eigenbrod, S., Lutz, J., Ledderose, C., Egensperger, R., Tonn, J. C., Kretzschmar, H. A., Hinske, L. C., & Kreth, F. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017156 · Cited by 122
Christmann, M., Nagel, G., Horn, S., Krahn, U., Wiewrodt, D., Sommer, C., & Kaina, B. (2010) · International Journal of Cancer · doi:10.1002/ijc.25229 · Cited by 117
Lalezari, S., Chou, A. P., Tran, A. N., Solis, O. E., Khanlou, N., Chen, W., Li, S., Carrillo, J., Chowdhury, R., Selfridge, J. M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos308 · Cited by 116
Wiewrodt, D., Nagel, G., Dreimüller, N., Hundsberger, T., Perneczky, A., & Kaina, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23219 · Cited by 114
Shah, N., Lin, B., Sibenaller, Z. A., Ryken, T. C., Lee, H., Yoon, J., Rostad, S. W., & Foltz, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016146 · Cited by 112
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma
Indraccolo, S., Lombardi, G., Fassan, M., Pasqualini, L., Giunco, S., Marcato, R., Gasparini, A., Candiotto, C., Nalio, S., Fiduccia, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1892 · Cited by 108
Bell, E. H., Pugh, S. L., McElroy, J. P., Gilbert, M. R., Mehta, M. P., Klimowicz, A. C., Magliocco, A. M., Bredel, M., Robe, P. A. J. T., Grosu, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6020 · Cited by 107
Self-citationMelguizo, C., Prados, J. C., González, B., Ortíz, R., Concha, Á., Alvarez, P. J., Madeddu, R., Perazzoli, G., Oliver, J. A., López, R., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-250 · Cited by 95
Pandith, A. A., Qasim, I., Zahoor, W., Shah, P., Bhat, A. R., Sanadhya, D., Shah, Z. A., & Naykoo, N. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-25169-2 · Cited by 88
Pieper, R. O., Patel, S. A., Ting, S. A., Futscher, B. W., & Costello, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13916 · Cited by 87
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
Radke, J., Koch, A., Pritsch, F., Schumann, E., Misch, M., Hempt, C., Lenz, K., Loebel, F., Paschereit, F., Heppner, F. L., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0745-z · Cited by 81
Brigliadori, G., Foca, F., Dall’Agata, M., Rengucci, C., Melegari, E., Cerasoli, S., Amadori, D., Calistri, D., & Faedi, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2116-y · Cited by 70
Nagane, M., Kobayashi, K., Ohnishi, A., Shimizu, S., & Shiokawa, Y. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hym132 · Cited by 62
Treatment considerations for MGMT-unmethylated glioblastoma
Taylor, J. W., & Schiff, D. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0507-z · Cited by 60
The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide
Moen, E. L., Stark, A. L., Zhang, W., Dolan, M. E., & Godley, L. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0924 · Cited by 50
Brell, M., Ibáñez, J., & Tortosa, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-35 · Cited by 50
Mur, P., de Lope, Á. R., Diaz-Crespo, F. J., Hernández‐Iglesias, T., Ribalta, T., Fiaño, C., García, J. F., REY, J. A., Mollejo, M., & Meléndez, B. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1738-9 · Cited by 48
MGMT testing allows for personalised therapy in the temozolomide era
Dullea, A., & Marignol, L. H. (2015) · Tumor Biology · doi:10.1007/s13277-015-4240-2 · Cited by 34
Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients
Hsu, C., Ho, H., Lin, S., Chen, M., Hsu, S. P., Yen, Y., Guo, W., & Ho, D. M. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000331 · Cited by 20
Trabelsi, S., Mama, N., Ladib, M., Karmeni, N., Mastouri, M. H., Chourabi, M., Mokni, M., Tlili, K., Krifa, H., Yacoubi, M. T., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1381-0 · Cited by 15
Research works printed but not linked: 7
- Cao, 2009, The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas, Neurosurgery, 65, 866, 10.1227/01.NEU.0000357325.90347.A1 · doi:10.1227/01.neu.0000357325.90347.a1
- Mason, 2012, MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry, J. Cancer Res. Clin. Oncol., 138, 1789, 10.1007/s00432-012-1312-1 · doi:10.1007/s00432-012-1312-1
- Wang, 2017, Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas, Pathol. Res. Pract., 213, 1489, 10.1016/j.prp.2017.10.007 · doi:10.1016/j.prp.2017.10.007
- Dahlrot, 2018, Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis, Neuropathol. Appl. Neurobiol., 44, 172, 10.1111/nan.12415 · doi:10.1111/nan.12415
- Brandes, 2017, Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications, Oncologist, 22, 432, 10.1634/theoncologist.2016-0254 · doi:10.1634/theoncologist.2016-0254
- Chen, 2013, MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis, Arch. Med. Res., 44, 281, 10.1016/j.arcmed.2013.04.004 · doi:10.1016/j.arcmed.2013.04.004
- Sonoda, 2010, O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma, Int. J. Clin. Oncol., 15, 352, 10.1007/s10147-010-0065-6 · doi:10.1007/s10147-010-0065-6
Cited by
Aberrant RNA methylation triggers recruitment of an alkylation repair complex
Tsao, N., Brickner, J. R., Rodell, R., Ganguly, A., Wood, M., Oyeniran, C., Ahmad, T., Sun, H., Bacolla, A., Zhang, L., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.024 · Cited by 46
Metadata
- Authors
- Butler, M., Pongor, L., Su, Y.-T., Xi, L., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., & Wu, J.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 6
- Issue
- 5
- Pages
- 380-391
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W3012959001
- Cited by
- 342
- References
- 52
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.